Role of ancillary studies in fine-needle aspiration from selected tumors

Cancer Cytopathology

Volumn 120, Issue 3, 2012, Pages 145-160

  Schmitt, Fernando ^a,b   Barroca, Helena ^c  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Diagnosis; Fine needle aspiration cytology; Immunocytochemistry; Molecular techniques; Target therapies

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; K RAS PROTEIN; PANITUMUMAB; TUMOR MARKER;

ALK GENE; ATYPICAL LIMPOMATOUS TUMOR; CANCER LOCALIZATION; CANCER RESISTANCE; CHROMOSOME TRANSLOCATION 11; CLEAR CELL CARCINOMA; COLON CANCER; CYTOPATHOLOGY; DIAGNOSTIC ACCURACY; DIGESTIVE SYSTEM CANCER; EGFR GENE; FINE NEEDLE ASPIRATION BIOPSY; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE MUTATION; HUMAN; IMMUNOCYTOCHEMISTRY; KIDNEY CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MESOBLASTIC NEPHROMA; METASTASIS; MYXOID TUMOR; NEOPLASM; NEPHROBLASTOMA; NONHUMAN; ONCOGENE K RAS; PANCREAS CANCER; PHENOTYPE; PREDICTION; PREOPERATIVE EVALUATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHABDOID TUMOR; SENSITIVITY AND SPECIFICITY; SOFT TISSUE TUMOR; SOLID TUMOR; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; COMPARATIVE STUDY; CYTODIAGNOSIS; FEMALE; GASTROINTESTINAL TUMOR; GENETICS; HOSPITAL MANAGEMENT; IMMUNOHISTOCHEMISTRY; KIDNEY TUMOR; LUNG TUMOR; MALE; METABOLISM; METHODOLOGY; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; NEEDLE BIOPSY; PATHOLOGY; PORTUGAL; THYROID TUMOR;

ANCILLARY SERVICES, HOSPITAL; BIOPSY, FINE-NEEDLE; CYTODIAGNOSIS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MOLECULAR BIOLOGY; MOLECULAR TARGETED THERAPY; NEOPLASMS; PORTUGAL; SENSITIVITY AND SPECIFICITY; SOFT TISSUE NEOPLASMS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864015884     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20197     Document Type: Review

References (68)

1. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-285.
2. Fowler LJ, Lachar WA. Application of immunohistochemistry to cytology. Arch Pathol Lab Med. 2008;132: 373-383.
3. Fetsch PA, Simir A, Brosky K, Abati A. Comparison of the 3 commonly used cytologic preparations in effusion immunocytochemistry. Diagn Cytopathol. 2001;26:61-66.
4. Schmitt FC, Longatto-Filho A, Valent A, Vielh P. Molecular techniques in cytopathology practice. J Clin Pathol. 2008;61:258-267.
5. Akerman M, Alves VA, Bubendorf L, et al. How technology is reshaping the practice of nongynecologic cytology. Acta Cytol. 2007;51:123-152.
6. Killian JK, Walker RL, Suuriniemi M, et al. Archival fineneedle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. J Mol Diagn. 2010;12:739-745.
7. Longatto-Filho A, Goncalves AE, Martinho O, Schmitt FC, Reis RM. Liquid-based cytology in DNA-based molecular research. Anal Quant Cytol Histol. 2009;31:395-400.
8. Wohlschlaeger J, Worm K, Schmitt F, Davidson B, Totsch M. Assessment of DNA, small NCRNA and MRNA detection over time in liquid-based cytology specimens [abstract]. Cytopathology. 2009;20:67.
9. Tanas MR, Rubin BP, Tubbs RR, et al. Utilization of fluorescence in situ hybridization in the diagnosis of 230 mesenchymal neoplasms: an institutional experience. Arch Pathol Lab Med. 2010;134:1797-1803.
10. Colasacco C, Mount S, Leiman G. Documentation of immunocytochemistry controls in the cytopathologic literature: a meta-Analysis of 100 journal articles. Diagn Cytopathol. 2011;39:245-250.
11. Travis WD, Rekhtman N, Riley GJ, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol. 2010; 5:411-414.
12. Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63 and EGFR mutational analysis. J Thoracic Oncol. 2010;5: 436-441.
13. Loo PS, Thomas SC, Nicolson MC, Fyfe M, Kerr KM. Subtyping of undifferentiated non-small cell carcinoma in bronchial biopsy specimens. J Thoracic Oncol. 2010;5:442-447.
14. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer. 2011;117:3416-3423.
15. Stoll LM, Johnson MW, Gabrielson E, et al. The utility of Napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathol. 2010;118:441-449.
16. Kalhor N, Zander DS, Liu J. TTF-1 and P63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously Pap-stained cytologic material. Mod Pathol. 2006;19: 1117-1123.
17. Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to lung. Arch Pathol Lab Med. 2008;132:384-396.
18. Rosenwald S, Gilad S, Benjamin S, et al. Validation of a microRNA-based qRT-PCR test for accurate identification of a tumor tissue origin. Mod Pathol. 2010;23:814-823.
19. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin. 2011;61:91-112.
20. da Cunha Santos G, Saieg MA, Geddie W, Leighl N. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer Cytopathol. 2011;119:80-91.
21. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455:1069-1075.
22. Lim EH, Zhang SL, Li JL, et al. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol. 2009;4:12-21.
23. Molina-Vila MA, Bertran-Alamillo J, Reguart N, et al. A sensitive method for detecting EGFR mutations in nonsmall cell lung cancer samples with few tumor cells. J Thorac Oncol. 2008;3:1224-1235.
24. Smith GD, Chadwick BE, Willmore-Payne C, Bentz JS. Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilizing high-resolution melting amplicon analysis. J Clin Pathol. 2008;61:487-493.
25. Billah S, Stewart J, Staerkel G, Chen S, Gong Y, Guo M. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol. 2011;119:111-117.
26. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N Engl J Med. 2010;363:1693-1703.
27. Sun L, Zhang Q, Luan H, Zhan Z, Wang C, Sun B. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice [serial online]. J Exp Clin Cancer Res. 2011;30:30.
28. Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol. 2009;132:658-665.
29. Bartolazzi A, Gasbarri A, Papotti M, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet. 2001;357: 1644-1650.
30. Khurana KK, Truong LD, LiVolsi VA, Baloch ZW. Cytokeratin 19 immunolocalization in cell block preparation of thyroid aspirates. An adjunct to fine-needle aspiration diagnosis of papillary thyroid carcinoma. Arch Pathol Lab Med. 2003;127:579-583.
31. Hermmann ME, Livolsi VA, Pasha TL, et al. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med. 2002;126:710-713.
32. Mills LJ, Poller DN, Yiangou C. Galectin-3 is not useful in thyroid FNA. Cytopathology. 2005;16:132-138.
33. Pazaitou-Panayiotou K, Mygdakos N, Boglou K, et al. The immunocytochemistry is a valuable tool in the diagnosis of papillary thyroid cancer in FNA's using liquid-based cytology [serial online]. J Oncol 2010:963926, 2010.
34. Eszlinger M, Paschkea R. Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumour specific mutations and gene expression patterns. Mol Cell Endocr. 2010;322:29-37.
35. Trovisco V, Soares P, Preto A, et al. Type and prevalence of BRAF mutations closely associated to papillary thyroid carcinoma histiotype and patient age but not with tumour aggressiveness. Virchows Arch. 2005;446:589-595.
36. Cerilli LA, Mills SE, Rumpel CA, et al. Interpretation of RET immunostaining in follicular lesions of thyroid. Am J Clin Pathol. 2002;118:186-193.
37. Rossi ED, Raffaelli M, Minimo C, et al. Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fine needle aspiration biopsies. Cancer. 2005;105:87-95.
38. Fusco A, Chiappetta G, Hui P, et al. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for early precursors of papillary cancer. Am J Pathol. 2002;160:2157-2167.
39. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94:2092-2098.
40. Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer. Thyroid. 2009;19:1351-1361.
41. Linwah Yip, Kebebew E, Milas M, et al. Summary statement: utility of molecular marker testing in thyroid cancer. Surgery. 2010;148:1313-1315.
42. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
43. Takeichi N, Ito H, Okamoto H, Matsuyama T, Tahara E, Dohi K. The significance of immunochemically staining calcitonin and CEA in fine-needle aspiration biopsy materials from medullary carcinoma of the thyroid. Jpn J Surg. 1989;19:674-678.
44. Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med. 2011;135:92-109.
45. Barroca H, Correia C, Castelo S. Cytologic and cytogenetic diagnosis of pediatric renal cell carcinoma associated with t(X;17). Acta Cytol. 2008;52:384-386.
46. Malouf GG, Camparo P, Molinie V, et al. Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. J Urol. 2011;185:24-29.
47. Bayindir P, Guillerman RP, Hicks MJ, Chintagumpala MM. Cellular mesoblastic nephroma (infantile renal fibrosarcoma): institutional review of the clinical, diagnostic imaging, and pathologic features of a distinctive neoplasm of infancy. Pediatr Radiol. 2009;10:1066-1074.
48. Gadd S, Sredni ST, Huang CC, et al. Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets. Lab Invest. 2010;90:724-738.
49. Toll AD, Witkiewicz AK, Bibbo M. Expression of K homology domain containing protein (KOC) in pancreatic cytology with corresponding histology. Acta Cytol. 2009;53:123-129.
50. Ali S, Cohen C, Little JV, et al. The utility of SMAD4 as a diagnostic immunohistochemical marker for pancreatic adenocarcinoma, and its expression in other solid tumors. Diagn Cytopathol. 2007;35:644-648.
51. Pitman M, Lewasdrowski K, Shen J, et al. Pancreatic cysts: preoperative diagnosis and clinical management. Cancer Cytopathol. 2010;25:1-13.
52. Schoedel KE, Finkelstein SD, Ohori NP. K-RAS and microsatellite marker analysis of fine-needle aspirates from intraductal papillary mucinous neoplasms of the pancreas. Diagn Cytopathol. 2006;34:605-608.
53. Khalid A, Zahid M, Finkelstein SD, et al. Pancreatic cysts fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc. 2009; 69:1095-1102.
54. Antonescu CR. The GIST paradigm: lessons for other kinase-driven cancers. J Pathol. 2011;223:251-261.
55. Gomes AL, Bardales RH, Milanezi F, et al. Molecular analysis of c-Kit and PDGFRA in GISTs diagnosed by EUS. Am J Clin Pathol. 2007;127:1-8.
56. Hwang DG, Qian X, Hornick JL. DOG1 antibody is a highly sensitive and specific marker for gastrointestinal stromal tumors in cytology cell blocks. Am J Clin Pathol. 2011;35:448-453.
57. Lievre A, Bachet J, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374-379.
58. Oliveira C, Velho S, Moutinho C, et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene. 2007;26:158-163.
59. Malapelle U, Bellevicine C, Russo A, et al. KRAS testing on colo-rectal carcinoma cytological imprints. Diagn Cytopathol. 2011;39:274-277.
60. Bovee J, Hogendoorn PCW. Molecular pathology of sarcomas: concepts and clinical implications. Virchows Arch. 2010;456:193-199.
61. Lazar A, Abruzzo LV, Pollock RE, et al. Molecular diagnosis of sarcomas: chromosomal translocation in sarcomas. Arch Pathol Lab Med. 2006;130:1199-1208.
62. Yu Z, Parham DM. Paediatric soft tissue tumors: from histology to molecular diagnosis. Diagn Histopathol. 2009; 15:524-539.
63. Klijanienko J, Couturier J, Bourdeaut F, et al. Fine-needle aspiration as a diagnostic technique in 50 cases of primary Ewing sarcoma/peripheral neuroectodermal tumor. Institut Curie's experience [published online ahead of print November 9, 2010]. Diagn Cytopathol. 2010.
64. Kumagai A, Motoi T, Tsuji K, Imamura T, Fukusato T. Detection of SYT and EWS gene rearrangements by dualcolor break-Apart CISH in liquid-based cytology samples of synovial sarcoma and Ewing sarcoma/primitive neuroectodermal tumor. Am J Clin Pathol. 2010;134:323-331.
65. Thomson TA, Klijanienko J, Couturier J, et al. Fine-needle aspiration of renal and extrarenal rhabdoid tumors: the experience of the Institut Curie regarding 20 tumors in 13 patients. Cancer Cytopathol. 2011; 119:49-57.
66. Al-Maghraby HQ, Khalbuss WE, Rao UN, Cieply K, Dacic S, Monaco SE. Fine needle aspiration biopsy diagnosis of dedifferentiated liposarcoma: cytomorphology and MDM2 amplification by FISH [serial online]. Cytojournal. 2010;7:5.
67. Di Lorito A, Schmitt F. (Cyto)pathology and sequencing: next (or last) generation [published online ahead of print May 2, 2011]Diagn Cytopathol. 2011.
68. Eloy C, Amendoeira I, Schmitt FC. Fine-needle aspiration as an alternative method for frozen tissue banking of breast cancer. Diagn Cytopathol. 2009;37:76-77.